Nkarta, Inc. (NKTX)
NASDAQ: NKTX · Real-Time Price · USD
2.150
+0.060 (2.87%)
At close: Aug 3, 2026, 4:00 PM EDT
2.130
-0.020 (-0.93%)
After-hours: Aug 3, 2026, 7:34 PM EDT
Nkarta Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
108
Market Cap
153.82M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caribou Biosciences | 11.20M |
| Cibus | 4.29M |
| Korro Bio | 3.84M |
| Milestone Pharmaceuticals | 1.78M |
| Molecular Partners AG | 856.30K |
| YD Bio | 510.36K |
| Lexaria Bioscience | 194.00K |
| Entera Bio | 42.00K |
NKTX News
- 11 days ago - Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development - GlobeNewsWire
- 4 weeks ago - Nkarta Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Transcripts
- 5 weeks ago - Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewsWire
- 5 weeks ago - Nkarta initiated with a Buy at TD Cowen - TheFly
- 7 weeks ago - Nkarta Transcript: AGM 2026 - Transcripts
- 2 months ago - Nkarta price target lowered to $9 from $25 at Evercore ISI - TheFly
- 2 months ago - Nkarta reports Q1 EPS (37c), consensus (37c) - TheFly
- 2 months ago - Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights - GlobeNewsWire